PubRank

Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors

Clinical Trial ID NCT01876511

PubWeight™ 34.86‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01876511

Top papers

Rank Title Journal Year PubWeight™‹?›
1 PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015 13.08
2 The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2014 3.32
3 Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017 2.69
4 Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol 2015 1.45
5 PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol 2016 1.40
6 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
7 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
8 New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015 1.02
9 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
10 Advances in the management of gastrointestinal cancers--an upcoming role of immune checkpoint blockade. J Hematol Oncol 2015 0.91
11 From mice to humans: developments in cancer immunoediting. J Clin Invest 2015 0.90
12 Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma. Exp Mol Med 2015 0.89
13 Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Onco Targets Ther 2015 0.88
14 Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. Clin Cancer Res 2016 0.83
15 Current progress in immunotherapy for pancreatic cancer. Cancer Lett 2015 0.83
16 Targeted therapy for advanced gastric cancer: A review of current status and future prospects. World J Gastrointest Oncol 2015 0.82
17 Immune checkpoint blockade in microsatellite instable colorectal cancers: Back to the clinic. Oncoimmunology 2015 0.81
18 Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016 0.81
19 Immune Therapy in GI Malignancies: A Review. J Clin Oncol 2015 0.81
20 Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett 2015 0.78
21 Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res 2015 0.78
22 Immunotherapy in human colorectal cancer: Challenges and prospective. World J Gastroenterol 2016 0.75
23 Prime time for immune-checkpoint targeted therapy at ASCO 2015. Oncoimmunology 2015 0.75
24 Colorectal clinical trials: what is on the horizon? Future Oncol 2016 0.75
25 The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer. Cancers (Basel) 2015 0.75
26 Novel Therapies in Development for Metastatic Colorectal Cancer. Gastrointest Cancer Res 2014 0.75
27 Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World J Gastroenterol 2016 0.75
Next 100